SAN ANTONIO (EGMN) - The novel bone-strengthening agent denosumab markedly increased bone mineral density at both trabecular and cortical sites throughout the skeleton in its first phase III clinical trial in breast cancer patients on adjuvant aromatase inhibitor therapy, Dr. Georgiana K. Ellis reported at the annual San Antonio Breast Cancer Symposium. The investigational agent's side effect profile was essentially that of placebo. Not a single treatment-related serious adverse event occurred in...